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Objectives: We sought to evaluate the effect of AF on the immediate and
long-term (23 years) outcome of patients undergoing BMV.
Methods: The immediate procedural and the long-term clinical outcome
after BMV of 139 patients with AF were collected and compared with those
of 381 patients in normal sinus rhythm (NSR). 
Results: Patients with AF were older (43.3 vs. 29.7 years; p < 0.001), had
frequently a history of systemic embolism (9.4% vs. 1.6%, p< 0.001) and of
mitral commissurotomy (28.1% vs. 19.4%, p=0.035). Patients with AF had
more frequently a Wilkins score > 8 (51.4% vs. 30.9%, p <0.001), a larger left
atrium (41cm2 vs. 32cm2, p= 0.001) and a lower transmitral gradient (11.1
mmhg vs. 16.6 mmhg, p < 0.001).
BMV was equally successful in the two groups (90.6% vs. 94%,
p=0.187) but resulted in a smaller post BMV area (2cm2 vs. 2.15cm2,
p=0.012) with a lower mitral valve area gain (0.9cm2 vs. 1 C, p=0.015).
BMV was not associated with a higher risk of complications (4.3% vs.
4.7%, p= 0.844).
After a mean follow-up of 74 months, patients with AF had the same
rate of restenosis (28.3% vs. 25.6%, p=0.96) but required more frequently
a mitral valve replacement (16.3% vs. 7.7%, p= 0.012). They also experi-
enced higher rates of systemic embolism (3.8% vs. 0.6%, p=0.018) and
had a lower rate of event free survival (52.2% vs 68.8%, p= 0.047). In the
group of patients in AF, predictive factors for combined adverse events
including death, restenosis, and systemic embolism. Predictive factors of
mitral valve replacement are: post BMV area < 2cm2 (OR: 2.5, 95% CI
[1.2; 5.18], p= 0.014), procedural complications including severe mitral
regurgitation and tamponnade (OR: 3.95, p= 0.009) and NYHA ≥ II during
follow up (OR: 3.46, p <0.001).
Conclusion: Our data support the fact that patients with AF have worse
immediate and long term outcomes after BMV. Post BMV area <2cm2,
procedural complications and dyspnea predict adverse events during
follow up.
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Tricuspid valve-in-valve (VIV) implantation has recently emerged as a
possible therapeutic option when a bioprosthetic valve degenerates. A French
retrospective study is reported. 
From 2010 to end 2014, 9 patients underwent tricuspid VIV implantation.
There were 4 females and 5 males. Pts were in functional NYHA class III. Seven
pts had congenital heart disease, 1 pt a rheumatic disease, 1 pt a cardiomyopathy.
Causes for implantation were tricuspid stenosis (n = 4), a mixed lesion combining
tricuspid stenosis and regurgitation (n = 4), and one tricuspid regurgitation. In
addition, 2 of them suffered from protein losing enteropathy (PLE).
Implantation was performed under general anaesthesia using a femoral
approach at a mean age of 29.5±18 years (9-60 years). Two pts underwent
pre-dilatation of the lesion and a pre-stenting was performed in 6. VIV
implantation was realized under pacing in 3 pts. A 22-mm Melody valve
(Medtronic) was implanted in 6 pts, and an Edwards Sapien valve in 3 (one
23-mm, one 26mm, and one 29-mm valve). Implantation succeeded in all
despite 2 embolizations (1 in RA and 1 in RV); the embolized stent could be
stabilized within the tricuspid annulus in both by a self-expandable stent
before subsequent successful VIV implantation using a second valved stent.
During follow-up (mean 10 months and up to 24 months), all pts but one were
clinically ameliorated (mean functional NYHA class II) including the 2 pts
with PLE (increase in albumin level). The mean tricuspid gradient decreased
significantly from 9.4±2.3mm Hg before to 3.9±0.4mm Hg after implantation.
Two pts died during follow-up but death was not valved stent related. 
To conclude, tricuspid VIV implantation is an effective procedure using
both the Melody and the Edwards Sapien valves. Knowledge of the true min-
imal diameter is the key point to choose the appropriate valved stent. This
promising technique has good immediate and mid-term results but further
studies with longer follow-up and including more pts are necessary 
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Introduction: Functional tricuspid regurgitation (TR) is probably the most
common and anticipated complication of left-sided heart valve pathology,
especially mitral valve diseases. Whether preoperative functional TR will
regress or progress after successful left-sided valve surgery is unknown. The
aim of this study was to identify the predictors of significant TR after suc-
cessful left-sided valve surgery.
Methods: A retrospective analysis was performed on a total of 56 patients
who underwent left-sided valve surgery (mitral or mitro-aortic valve surgery).
We have excluded patients who had organic TR.
All patients had complete clinical examination and echocardiographic
studies preoperatively and clinical and echocardiographic follow-up post-
operatively. 
Results: Mean operative age of patients was 49,3±13,7 years with a sex-
ratio of 0,8. Tricuspid annuloplasty was associated to left-sided valve surgery
in 18 (32%) patients. Postoperatively, significant TR was found in 13 patients
(23%) with a mean follow-up of 20,5±33 months. Patients with significant
postoperative TR were more often female (83% vs 48%, p = 0,03), had more
often a previous mitral commissurotomy (58% vs 23%, p=0,02) and showed a
higher prevalence of significant preoperative TR (69% vs 42%, p=0,04). Post-
operatively, residual pulmonary hypertension (p=0,04), dilatation of left
atrium (p=0,02) and dilatation of right cardiac cavities (p=0,01) were signifi-
cant risk factors for development or progression of TR after surgery. 
Conclusion: Late onset or progression of functional TR after successful
left-sided valve surgery is a significant clinical entity as it displays a great
impact on patient prognosis. So, the identification of clinical and echocardio-
graphic predictors of late TR allows an adequate screening of patients that will
require tricuspid valve repair at the time of initial left-sided valve surgery.
0407
Evaluation of the tricuspid annulus size: clinical implications from
comparison between 2D-transthoracic and 3D-transesophageal echo-
cardiography 
Julien Dreyfus, Guillaume Durand-Viel, C.Cimadevilla, Eric Brochet,
Alec Vahanian, David Messika-Zeitoun
CHU Bichat-Claude Bernard-APHP, Cardiologie, Paris, France
Background: Tricuspid annuloplasty is recommended during left-heart
valve surgery when tricuspid annulus (TA) is dilated, independently of the
degree of tricuspid regurgitation, but the methodology to measure TA and
thresholds are not clearly defined. We aimed to compare TA diameter (TAD)
measurements performed using bi-dimensional transthoracic echocardiography
(2D-TTE) in the 4 different views to three-dimensional measurements per-
formed during transesophageal echocardiography (3D-TEE) and to define
thresholds of TA enlargement for routine practice.
Methods: 2D-TTE measurement of the TAD was performed in para-
sternal long-axis view of the right ventricle inflow, parasternal short-axis,
apical 4-chamber (A4C) and sub-costal views in 195 prospectively enrolled
patients and 66 healthy volunteers. 3D dynamic volumetric datas of the TA
were also acquired by TEE using a matrix array transducer (X7-2t, Philips)
in the 195 patients. Multiplanar reconstructions were performed offline
using dedicated software (QLab7, Philips) to measure the long-axis (LA) of
the TA.
Results: In the 195 patients, TAD measurements were not different
between the 4 TTE views (P=0.13), but A4C was the most feasible and the
most reproducible method (Table). TAD measurement in A4C view by TTE
(3.90±0.62cm) was well correlated (r=0.84, p<0.0001) to LA by 3D-TEE
(4.33±0.63cm), but with a systematic 4mm underestimation. In the healthy
volunteers, mean value of TAD in A4C was 3.2±0.4cm or 1.8±0.23cm/m² and
the upper limit of 95% confidence interval was 4.2cm or 2.3cm/m².
